Back to results
US 11,442,069 B2Granted
Method of diagnosing cancer and diagnosis kit using measurement of NK cell activity
AssigneeAtgen Co., Ltd.
InventorsJae Myun Lee, Joo Chun Yoon, Sang Woo Park, Jong Sun Kim
Life of this patent
Estimating the term…
Abstract
Provided are a method for diagnosing cancer, a diagnosis kit and compositions useful for measurement of NK cell activity. The incidence of cancer may be diagnosed by monitoring changes in the in vivo immune system through measurement of NK cell activity in blood. Thus, the incidence of cancer may be readily predicted as described herein using a blood sample from a subject.
Claims33
A method of measuring natural killer (NK) cell activity, comprising:
- stimulating NK cells in a whole blood sample by incubating the whole blood sample with a composition comprising interleukin 15 and interleukin 12, thereby artificially activating the NK cells to generate and secrete NK cell-secreting cytokines;
- and
- measuring an amount of the NK cell-secreting cytokines secreted into the whole blood sample and using the amount as a measure of NK cell activity;
- wherein the whole blood sample is a human whole blood sample.
1 more element
A method of measuring natural killer (NK) cell activity, comprising:
- stimulating NK cells in a whole blood sample by incubating the whole blood sample with an agent comprising the isolated stimulating cytokine interleukin 2 in the form of a fusion protein with a stabilizing peptide, thereby artificially activating the NK cells to generate and secrete NK cell-secreting cytokines;
- and
- measuring an amount of the NK cell-secreting cytokines secreted into the whole blood sample and using the amount as a measure to evaluate NK cell activity;
- wherein the whole blood sample is a human whole blood sample.
1 more element
A method of measuring natural killer (NK) cell activity, comprising:
- stimulating NK cells in a whole blood sample by incubating the whole blood sample with an agent comprising at least one isolated stimulating cytokine selected from the group consisting of interleukin 2 and interleukin 15, thereby artificially activating the NK cells to generate and secrete NK cell-secreting cytokines;
- and
- measuring an amount of the NK cell-secreting cytokines secreted into the whole blood sample and using the amount as a measure to evaluate NK cell activity;
- wherein the at least one stimulating cytokine is in the form of a fusion protein with a stabilizing peptide.
1 more element
Dependencies are inferred from the claim text.